Lopez-Alcorocho Juan Manuel, Aboli Lucia, Guillen-Vicente Isabel, Rodriguez-Iñigo Elena, Guillen-Vicente Marta, Fernández-Jaén Tomás F, Arauz Santiago, Abelow Steve, Guillen-García Pedro
1 Department of Traumatology and Research Unit, Clinica CEMTRO, Madrid, Spain.
Cartilage. 2018 Oct;9(4):363-369. doi: 10.1177/1947603517693045. Epub 2017 Feb 15.
The aim of this work was to study the short- and mid-term effectiveness and safety of high-density autologous chondrocyte implantation (HD-ACI) in the first 50 patients with knee cartilage damage treated in our unit.
Fifty consecutive patients with cartilage lesions (Outerbridge grade III-IV) in the knee treated with HD-ACI were included in this study. Chondrocytes were isolated from a nonbearing cartilage area biopsy and were cultured until 40 to 50 million cells were obtained. Five million chondrocytes per cm of a porcine collagen type I/III membrane were implanted covering the defect. Procedure effectiveness was assessed by evaluating pain, swelling, and range of mobility (flexion and extension) at 6-, 12-, and 24-month follow-up. The International Knee Documentation Committee (IKDC) subjective evaluation form was used to evaluate symptoms and functions of the knee.
The percentage of patients with pain and swelling decreased progressively in the following visits, with differences being statistically significant ( P < 0.001 and P = 0.040, respectively). IKDC scores improved progressively throughout the 24-month follow-up ( P < 0.001). Thus, the mean IKDC score improvement was 26.3 points (95% confidence interval [CI] = 18.2-34.4 points) at 12 months and 31.0 points (95% CI = 22.9-39 points) at 24 months. No significant differences were found when performing extension ( P = 0.112). Flexion significantly improved by 25.1° at 24-month follow-up ( P = 0.013).
HD-ACI is a safe and effective technique for the treatment of cartilage defects, improving clinical and subjective perception of knee functionality. These preliminary results encourage future studies comparing this technique with traditional ACI.
本研究旨在探讨高密度自体软骨细胞植入术(HD-ACI)对本单位收治的首批50例膝关节软骨损伤患者的短期和中期疗效及安全性。
本研究纳入了50例连续接受HD-ACI治疗的膝关节软骨损伤(Outerbridge III-IV级)患者。从非负重软骨区域活检中分离软骨细胞并进行培养,直至获得4000万至5000万个细胞。每平方厘米猪I/III型胶原膜植入500万个软骨细胞以覆盖缺损处。通过在6个月、12个月和24个月随访时评估疼痛、肿胀和活动度(屈伸)来评估手术效果。采用国际膝关节文献委员会(IKDC)主观评估表评估膝关节的症状和功能。
在随后的随访中,疼痛和肿胀患者的百分比逐渐下降,差异具有统计学意义(分别为P<0.001和P=0.040)。在整个24个月的随访中,IKDC评分逐渐提高(P<0.001)。因此,12个月时IKDC评分平均提高26.3分(95%置信区间[CI]=18.2-34.4分),24个月时提高31.0分(95%CI=22.9-39分)。伸直时未发现显著差异(P=0.112)。在24个月随访时,屈曲显著改善了25.1°(P=0.013)。
HD-ACI是一种治疗软骨缺损的安全有效技术,可改善膝关节功能的临床和主观感受。这些初步结果鼓励未来开展将该技术与传统ACI进行比较的研究。